Therapeutics Solutions International, Inc. announced on September 3, 2019, the recruitment of Feng Lin, MD, Ph.D., as Chief Scientific Officer. Dr. Lin has a stellar track record of drug development in the area of immunology and immuno-oncology having worked with the public company Inovio Pharmaceuticals, where he developed technologies for gene delivery and therapeutic DNA vaccines against cancer and infectious diseases in both R&D and clinical settings. Subsequently, Dr. Lin served as Director of Chinese Operations for MediStem Inc, which was acquired by the leading biotech company Intrexon on May 2014. It was the rapid clinical translation model developed by Dr. Lin at MediStem that resulted in the company's accelerated FDA clearance to begin clinical trials, which resulted in the sale of the company.